PART 0 1 产品定义及统计范围 注射器是一种用于将液体注入或从体内抽出液体的医疗设备。它由一个活塞和一个圆柱形的注射管组成，活塞 与注射管紧密配合，使用户能够通过安装在注射管顶部的针头进行吸液和推液操作。注射器设计为单次使用， 以防止交叉污染并降低感染风险。注射器广泛应用于医疗环境中，具有不同的尺寸和类型，以满足不同的医疗 需求，包括疫苗接种、药物注射和血液采样等。 PART 0 2 注射器行业目前现状分析 PART 0 3 注射器发展趋势 安全注射器全面推广 市场需求持续增长，疫苗和慢性病治疗是主要驱动力 全球注射器市场需求近年来显著增长，主要受疫苗接种和慢性病治疗需求推动。COVID-19大流行期间，全球疫 苗注射器需求激增，2021-2022年达到高峰。尽管疫情后需求有所回落，但常规免疫规划（如流感、HPV、肝炎 疫苗）仍保持稳定增长。此外，糖尿病、癌症等慢性病患者数量上升，胰岛素注射器、化疗药物输送等需求增 加。根据国际糖尿病联盟（IDF）数据，全球约5.3亿糖尿病患者。新兴市场（如印度、非洲）的医疗体系扩张 也推动注射器需求增长。 安全注射器和预充式注射器成为高端市场主流 传统一次性注射器市场 ...

Financial Performance - Revenue remained flat year-over-year at RMB6644 million[9,46] - Adjusted net profit decreased by 61% year-over-year to RMB1022 million, attributed to pricing decreases and marketing expenses[9,46] - Overseas sales increased by 40% year-over-year, reaching RMB1624 million, representing 244% of total sales[11,46] - R&D expenses reached RMB320 million, accounting for 47% of revenue[11] Business Segments - General medical device segment revenue was RMB3300 million, flat year-over-year, with a profit of RMB490 million, down by 171%[16] - Pharma packaging segment revenue was RMB1170 million, flat year-over-year, with a profit of RMB450 million, down by 58%[24] - Orthopaedics segment revenue was RMB730 million, slightly down by 16% year-over-year, but profit increased significantly by 743% to RMB150 million[27] - Blood management segment revenue increased by 81% year-over-year to RMB450 million, while profit decreased by 53% to RMB31 million[37] Strategic Initiatives - The company plans to maintain a dividend payout ratio at 50%[52] - Total production capacity for blood bags is expected to exceed 100 million units in 2025[37] - Auto injectors recorded strong sales in China, with H1 sales up by approximately 200%, accounting for approximately 3% of segment sales[24]